Fresh analysis reveals that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who stop conventional diet and exercise programs.
Findings released in a prominent health publication demonstrates that while obese individuals often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these drugs must be aware of the potential of quick weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass in about a year and a half.
Analyzing Approaches
The study, which looked at dozens of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills.
Researchers note that people who lose weight through diet and exercise generally see a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Nutrition scientists suggest the mechanism of the jabs is key to understanding the heightened rebound.
These medications copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, due to the high risk of relapse, the therapy is often long-term.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the long-term nature of obesity," akin to managing diseases like hypertension.
Patient Experiences
Individuals who have stopped the medication describe a intense return of cravings.
"It was like a trigger flipping and I was suddenly extremely hungry," described one woman.
The struggle is compounded if users have not developed lasting dietary or behavioural changes during therapy.
Significant Use
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and long-term success relies on integrated lifestyle management.
